Tag: Viking Therapeutics

Shares of Viking Therapeutics experienced a notable upswing this week, climbing 7.4% on Wednesday to close at $26.82. The catalyst ...

Shares of Viking Therapeutics are experiencing significant turbulence as conflicting forces within the biotechnology sector create a challenging landscape for ...

Viking Therapeutics experienced significant selling pressure yesterday as investors reacted to Pfizer's unexpected acquisition of competitor Metsera. The biotech firm's ...

Viking Therapeutics shares are entering a pivotal period as the market anticipates key developments. Following August's volatility triggered by disappointing ...

Viking Therapeutics shares registered substantial double-digit gains late last week, propelled by favorable sector developments and sustained bullish sentiment among ...

Shares of Viking Therapeutics experienced substantial gains following the release of impressive Phase 2 trial results for its oral formulation ...

Viking Therapeutics shares are experiencing a severe sell-off, extending recent losses with a further 1.64% decline over the past trading ...

Viking Therapeutics finds itself navigating turbulent waters as its stock experiences a pronounced downward trajectory. Investor confidence has been significantly ...

Investors are reassessing Viking Therapeutics' clinical trial data as concerns emerge about patient discontinuation rates in the study of oral ...

The obesity treatment market is becoming increasingly competitive as multiple pharmaceutical companies advance their GLP-1 receptor agonist candidates. Viking Therapeutics ...